@article{10902/24498,
year = {2022},
url = {http://hdl.handle.net/10902/24498},
abstract = {Head and neck squamous cell carcinoma is the sixth leading cancer in the world. This cancer is difficult to treat and is characterized by recurrences that are often fatal. This cancer is generally removed surgically, but it often regrows from the edges of the lesion from where most recurrences reappear. In this study, we have investigated if the expression of GB3 in human cell lines, tissues from patient biopsies, and a murine animal model could be used as an early and determinant marker of HNC. We found that in all the investigated systems, this marker appears in neoplastic cells from the very early stages of their malignant transformation. Our conclusions support the hypothesis that GB3 is a reliable and independent target for HNC identification and selective delivery of treatments. Furthermore, we show that the level of expression of this marker correlates with the degree of malignancy of the tumor. These studies suggest that GB3 may provide the basis for the early identification and new targeted therapies for head and neck cancer.},
organization = {This research was funded by ISCIII Projects ref. PI19/00349, DTS19/00033, co-funded by ERDF/ESF, “Investing in your future”; NanoBioApp Research Network (MINECO-17-MAT2016-81955-REDT), COST action Nano2Clinic CA17140, and IDIVAL for the INNVAL 19/12 and INNVAL20/13 projects.},
publisher = {MDPI AG},
publisher = {Biomedicines 2022, 10(4), 732},
title = {Gb3/cd77 is a predictive marker and promising therapeutic target for head and neck cancer},
author = {García-Hevia, Lorena and Muñoz Guerra, Débora and Casafont Parra, Íñigo and Morales Angulo, Carmelo and Ovejero Gómez, Víctor Jacinto and Lobo, David and López Fanarraga, Mónica},
}